Dr. Angela Steineck, MD
Claim this profileChildren's Hospital of Wisconsin
Studies Neuroblastoma
Studies Ganglioneuroblastoma
5 reported clinical trials
14 drugs studied
Area of expertise
1Neuroblastoma
MYC positive
Stage IV
2Ganglioneuroblastoma
MYC positive
Stage IV
Affiliated Hospitals
Clinical Trials Angela Steineck, MD is currently running
Dinutuximab + Chemotherapy
for High-Risk Neuroblastoma
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab binds to the neuroblastoma cells, it helps signal the immune system to kill the tumor cells. This helps the cells of the immune system kill the cancer cells, this is a type of immunotherapy. When chemotherapy and immunotherapy are given together, during the same treatment cycle, it is called chemoimmunotherapy. This clinical trial randomly assigns patients to receive either standard chemotherapy and surgery or chemoimmunotherapy (chemotherapy plus dinutuximab) and surgery during Induction therapy. Chemotherapy drugs administered during Induction include, cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. These drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Upon completion of 5 cycles of Induction therapy, a disease evaluation is completed to determine how well the treatment worked. If the tumor responds to therapy, patients receive a tandem transplantation with stem cell rescue. If the tumor has little improvement or worsens, patients receive chemoimmunotherapy on Extended Induction. During Extended Induction, dinutuximab is given with irinotecan, temozolomide. Patients with a good response to therapy move on to Consolidation therapy, when very high doses of chemotherapy are given at two separate points to kill any remaining cancer cells. Following, transplant, radiation therapy is given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of Induction. The final stage of therapy is Post-Consolidation. During Post-Consolidation, dinutuximab is given with isotretinoin, with the goal of maintaining the response achieved with the previous therapy. Adding dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy may be better at treating children with newly diagnosed high-risk neuroblastoma.
Recruiting2 awards Phase 37 criteria
Lorlatinib + Standard Therapy
for Neuroblastoma
This phase III trial studies iobenguane I-131 or lorlatinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Lorlatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving iobenguane I-131 or lorlatinib and standard therapy may work better compared to lorlatinib and standard therapy alone in treating younger patients with neuroblastoma or ganglioneuroblastoma.
Recruiting2 awards Phase 322 criteria
More about Angela Steineck, MD
Clinical Trial Related4 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Angela Steineck, MD has experience with
- Dinutuximab
- Auricular Percutaneous Neurostimulation
- Sham Percutaneous Neurostimulation
- Iobenguane I-131
- Lorlatinib
- Cisplatin
Breakdown of trials Angela Steineck, MD has run
Neuroblastoma
Ganglioneuroblastoma
Unexplained Vomiting
Fibrolamellar Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Angela Steineck, MD specialize in?
Angela Steineck, MD focuses on Neuroblastoma and Ganglioneuroblastoma. In particular, much of their work with Neuroblastoma has involved MYC positive patients, or patients who are Stage IV.
Is Angela Steineck, MD currently recruiting for clinical trials?
Yes, Angela Steineck, MD is currently recruiting for 2 clinical trials in Milwaukee Wisconsin. If you're interested in participating, you should apply.
Are there any treatments that Angela Steineck, MD has studied deeply?
Yes, Angela Steineck, MD has studied treatments such as Dinutuximab, Auricular percutaneous neurostimulation, Sham percutaneous neurostimulation.
What is the best way to schedule an appointment with Angela Steineck, MD?
Apply for one of the trials that Angela Steineck, MD is conducting.
What is the office address of Angela Steineck, MD?
The office of Angela Steineck, MD is located at: Children's Hospital of Wisconsin, Milwaukee, Wisconsin 53226 United States. This is the address for their practice at the Children's Hospital of Wisconsin.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.